Jazz Pharmaceuticals (JAZZ) Short term Debt (2010 - 2026)

Jazz Pharmaceuticals' Short term Debt history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Short term Debt rose 3224.19% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (up 3224.19% YoY), while the FY2025 annual figure was $1.0 billion, up 3222.26% from the prior year.
• Short term Debt for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
• The five-year high for Short term Debt was $1.0 billion in Q1 2026, with the low at $31.0 million in Q1 2022.
• The 5-year median for Short term Debt is $31.0 million (2022), against an average of $401.0 million.
• The sharpest annual moves came in 2025 and 2026: Short term Debt sank 94.88% in 2025, then jumped 3224.19% in 2026.
• Jazz Pharmaceuticals' Short term Debt stood at $31.0 million in 2022, then jumped by 1851.46% to $605.0 million in 2023, then sank by 94.88% to $31.0 million in 2024, then surged by 3222.26% to $1.0 billion in 2025, then climbed by 0.06% to $1.0 billion in 2026.
• Business Quant data shows JAZZ's Short term Debt at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.